Semaglutide / Tirzepatide Metabolic Program

GLP-1 receptor agonists (semaglutide, tirzepatide) are FDA-approved for type 2 diabetes and obesity, but their metabolic benefits extend well beyond weight loss. The 2023 SELECT trial (NEJM) showed a 20% reduction in major cardiovascular events in non-diabetic adults with obesity.\n\nDr. Razzak structures GLP-1 therapy as a 12-month medical programme rather than a standalone prescription. Each patient receives baseline metabolic profiling (HbA1c, fasting insulin, lipid panel, liver enzymes, body composition via DEXA), a personalised titration schedule, and monthly clinical check-ins to monitor response, adjust dosing, and address side effects.\n\nNutrition coaching, resistance training prescription, and protein-target optimisation are integrated to preserve lean mass during weight loss — a critical longevity consideration.\n\nThis programme is for adults with metabolic dysfunction, insulin resistance, or persistent body composition issues despite lifestyle effort. Suitability is assessed during the initial consultation.